en Oncology Oncology Original Article Original Article <span style="font-size:14px;"><span style="font-family:Times New Roman;"><span style="color:#0000ff;"><strong><em>Background</em></strong><em>:</em></span> Pre-operative chemoradiotherapy (NACRT) of patients with proximal gastric and esophagogastric junction (EGJ) adenocarcinoma may result in increased local control and improved patients&rsquo; survival rate. This study aimed to investigate the effect of NACRT on resectability of tumor in patients with proximal gastric and EGJ adenocarcinoma.<br> <span style="color:#0000ff;"><strong><em>Methods</em></strong><em>:</em></span> In this single-arm clinical trial, patients with locally advanced proximal gastric and EGJ adenocarcinoma were included. Two courses of paclitaxel/carboplatin chemotherapy alone followed by NACRT with a similar treatment regimen and a total radiation dose of 45-50.4/1.8-2 Grays were prescribed. After surgery, patients were evaluated for resection rate, pathologic response rate, and post-surgical complications.<br> <span style="color:#0000ff;"><strong><em>Results</em></strong><em>:</em> </span>A total of 61 patients with a mean age of 65.9 years participated. Grades 1 and 2 were the most prevalent side effects, with grade 3 being the worst grade and exhibiting as leukopenia (4.9%) and thrombocytopenia (1.6%). 25 (41%) patients underwent surgery after NACRT. Post-surgery complication was reported in 20% of cases (including 8% mortality and 12% morbidity). R0 and R2 resection was observed in 88% and 12% of cases, respectively. Complete pathologic-response was achieved in 24% of patients.<br> <span style="color:#0000ff;"><strong><em>Conclusion</em></strong><em>:</em></span> Paclitaxel/carboplatin based neoadjuvant chemotherapy was associated with potential resectability and appropriate pathologic response in patients with locally advanced proximal gastric and EGJ adenocarcinoma. However, by reducing patient tolerance to complete courses of weekly chemotherapy, induction chemotherapy lowered the effectiveness of concurrent chemotherapy and radiotherapy (as a sensitizing agent). Hence, induction chemotherapy proved to be more unbeneficial causing delayed treatment and reducing concurrent chemoradiotherapy tolerance.</span></span> neoadjuvant chemoradiotherapy, proximal gastric adenocarcinoma, esophagogastric junction (EGJ) adenocarcinoma 256 262 http://caspjim.com/browse.php?a_code=A-10-1860-1&slc_lang=en&sid=1 Seyed Amir Aledavood aledavooda@mums.ac.ir 100319475328460029320 100319475328460029320 No Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran Kazem Anvari AnvariK@mums.ac.ir 100319475328460029321 100319475328460029321 No Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran Soodabeh Shahidsales ShahidSalesS@mums.ac.ir 100319475328460029322 100319475328460029322 No Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran Sare Hosseini HosseiniS@mums.ac.ir 100319475328460029323 100319475328460029323 No Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran Ali Emadi Torghabeh EmadiTA@mums.ac.ir 100319475328460029324 100319475328460029324 No Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran Masume Masudian masudian61@gmail.com 100319475328460029325 100319475328460029325 Yes Kosar Hospital, Semnan University of Medical Sciences, Semnan, Iran